Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Reviews

|Includes:Prana Biotechnology Ltd (PRAN)

Market Trend Signal Reviews

PRAN

Prana Biotechnology Limited researches and develops therapeutic drugs for the treatment of neurological disorders in Australia. It primarily focuses on the Alzheimer‘s, Parkinson‘s, and Huntington‘s diseases, as well as various cancer and age-related macular degeneration. The company’s product line includes PBT2, which is in Phase IIb clinical trials for the treatment of Alzheimer’s disease, as well as in Phase IIa clinical trials to treat Huntington’s disease. Its preclinical products comprise PBT434 for the treatment of Alzheimer’s disease; and PBT519 to treat brain cancer. The company was formerly known as Prana Corporation Ltd. and changed its name to Prana Biotechnology Limited in January 2000. Prana Biotechnology Limited was founded in 1997 and is based in Parkville, Australia.

Market Trend Signal
Stock Analysis Software and Trading System

Stocks: PRAN